ArticleMaterials today. Bio2025
Dual-functional biomimetic periosteum incorporating engineered small extracellular vesicles for treating critical bone defect with soft tissue fenestration via TGF-beta1/SMAD pathway.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Critical bone defect with soft tissue fenestration poses a significant therapeutic challenge without the premise of barrier periosteum in situ for the relatively independent repair spaces of soft tissue and bone. Inspired by the regenerative functions of mesenchymal stem cells (MSCs)-derived small extracellular vesicles (sEVs) and the guided properties of in situ-generated periosteum, here we report the therapeutic benefits of dual-functional biomimetic periosteum (DBP) incorporating engineered sEVs for treating critical bone defect with soft tissue fenestration. We started our experiment with the construction of engineered sEVs via porous titanium-preconditioned MSCs-derived sEVs (Ti-sEVs). COL1A1 and MMP1 were enriched in Ti-sEVs with enhanced uptake efficiency of fibroblasts and bone marrow-derived MSCs for scarless soft tissue and bone repair abilities via TGF-beta1/SMAD pathway in vitro. DPB was constructed via the chemically crosslinking and lyophilized treatment of a xenogenic acellular dermal matrix. Incorporation and in vivo delivery of Ti-sEVs were successfully achieved via the controlled-release DPB with the characteristics of a loose surface facing the bone defect and a dense surface facing the soft tissue fenestration. DBP incorporating Ti-sEVs promoted the repair of the surrounding native periosteum in situ via the critical skull defect with skin fenestration models in rats. Bone repair with scarless soft tissue was achieved by enhanced angiogenesis and limited osteoclastic activity. Collectively, this dual-functional system could synergistically achieve critical bone defect regeneration with scarless soft tissue repair via TGF-beta1/SMAD pathway with the sustained release of Ti-sEVs, providing a promising strategy of engineered sEVs for preferable tissue regeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.